Integra LifeSciences Reduces Full-Year Revenue Guidance Due to Plant Flooding and Market Competition
Integra LifeSciences (IART) has lowered its full-year revenue guidance by $30 million following severe flooding at its Cincinnati manufacturing plant. The disruption is expected to cause significant production bottlenecks, with full manufacturing capabilities not anticipated to resume until the second quarter of 2027. Management estimates a $7 million impact on third-quarter revenue and an additional $15 million to $20 million hit in the fourth quarter. Despite these operational headwinds, the company's neurosurgery division showed resilience, growing organically by 6.5%. This growth helped offset losses in the tissue reconstruction segment, where competition has impacted market share for Urinary Bladder Matrix technology. On a positive note, Integra reported record operating cash flow of $96 million, driven by reduced compliance and facility start-up costs.
Tickers: $IART
Topics: earnings call operational headwinds revenue guidance reduction supply chain disruption
Read the full article at Motley Fool
Part of the story Integra LifeSciences Reduces Full-Year Revenue Guidance Due to Plant Flooding and Market Competition (3 articles)